Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report)'s share price traded up 4.7% during mid-day trading on Tuesday . The stock traded as high as $20.65 and last traded at $20.83. 190,397 shares were traded during trading, a decline of 49% from the average session volume of 376,418 shares. The stock had previously closed at $19.89.
Analyst Ratings Changes
Several research firms recently commented on CSTL. Robert W. Baird increased their target price on Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Stephens reiterated an "overweight" rating and set a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Finally, Guggenheim set a $30.00 target price on Castle Biosciences and gave the company a "buy" rating in a research report on Friday, March 28th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences currently has an average rating of "Buy" and a consensus target price of $38.75.
Check Out Our Latest Analysis on CSTL
Castle Biosciences Trading Up 1.2 %
The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average price of $21.66 and a 200-day moving average price of $26.85. The firm has a market capitalization of $620.46 million, a PE ratio of 107.56 and a beta of 1.11.
Insiders Place Their Bets
In other news, insider Derek J. Maetzold sold 22,639 shares of Castle Biosciences stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $20.12, for a total transaction of $455,496.68. Following the completion of the sale, the insider now directly owns 80,465 shares in the company, valued at approximately $1,618,955.80. This trade represents a 21.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,085 shares of company stock worth $748,045. 7.20% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Castle Biosciences
Several hedge funds have recently bought and sold shares of the stock. Covestor Ltd acquired a new stake in Castle Biosciences during the fourth quarter worth approximately $25,000. R Squared Ltd purchased a new stake in Castle Biosciences during the 4th quarter worth $42,000. GAMMA Investing LLC grew its position in Castle Biosciences by 1,865.8% in the first quarter. GAMMA Investing LLC now owns 4,364 shares of the company's stock valued at $87,000 after acquiring an additional 4,142 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Castle Biosciences during the fourth quarter worth about $128,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Castle Biosciences by 11.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock valued at $158,000 after acquiring an additional 604 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
See Also
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
